NCT02258828View on ClinicalTrials.gov

An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder

PHASE4CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

PTSD

Interventions

DRUG

Memantine

Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day

DRUG

Placebo

Matched placebo

Trial Locations (1)

68105

Omaha Veterans Affairs Medical Center, Omaha

Sponsors

Collaborators (1)

Forest Laboratories

All Listed Sponsors

collaborator

Forest Laboratories

INDUSTRY

lead

Sriram Ramaswamy

FED